The Pharma Letter6h
The Pharma Letter M&A roundup - October 2024
Pharmaceutical M&A came back with a bang during October, after a quiet September. Merck & Co (NYSE: MRK) and AbbVie (NYSE: ...
The Pharma Letter7h
AstraZeneca sees progress in obesity drug trials, highlights new oral option
AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...
The Pharma Letter10h
Vertex ups guidance again as results exceed estimates
US biopharma Vertex Pharmaceuticals was trading nearly 2% higher during pre-market trading on Tuesday. This followed Vertex’s ...
The Pharma Letter10h
PharmaMar gets $10 million milestone from Janssen for Yondelis
Spanish drugmaker PharmaMar Group today said it has received a payment of $10 million from Janssen Products, a Johnson & ...
The Pharma Letter12h
Transgene and ProBioGen join forces on cancer vaccines
French biotech Transgene today revealed it has entered into a license agreement with Germany-based contract development and ...
The Pharma Letter13h
Positive results for Neurocrine’s Ingrezza in tardive dyskinesia
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 ...